USANA Health Sciences reports Q4 net sales rise

USANA Health Sciences

17/02/2026 21:24

Overview

Nutritional supplements maker's fiscal Q4 net sales rose 6% yr/yr

Adjusted diluted EPS for fiscal Q4 fell 6% yr/yr

Company anticipates flat to 8% growth in fiscal 2026 net sales

Outlook

USANA projects fiscal 2026 consolidated net sales between $925 mln and $1 bln

Company expects fiscal 2026 net earnings between $20.3 mln and $26.6 mln

USANA anticipates Hiya net sales of $140 mln to $155 mln in fiscal 2026

Result Drivers

CUSTOMER STABILIZATION - Co noted signs of stabilization in active customer counts in core nutritional business, with modest sequential sales growth in key markets like China, US, and Canada

OMNICHANNEL GROWTH - Hiya and Rise brands experienced solid year-over-year growth, contributing to overall sales increase

CORE BUSINESS DECLINE - Core nutritional business sales fell 8% in FY 2025, reflecting challenges in customer acquisition

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$0.10


Analyst Coverage

Wall Street's median 12-month price target for USANA Health Sciences Inc is $39.00, about 86.6% above its February 13 closing price of $20.90

The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 10 three months ago

Press Release: ID:nBw7jfm7Ka

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)